In a first for St. Louis, patient completes new gene therapy to cure sickle cell disease
Martin Mwita, a 20-year-old from the Omaha area, is the first commercial sickle cell patient at St. Louis Children’s Hospital and in the region to receive a new gene therapy treatment approved by the FDA at the end of 2023. Mwita is under the care of Dr. Shelani Shenoy, a pediatric hematologist/oncologist with the Washington University School of Medicine.